MYOV Stock Overview
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men.
Myovant Sciences Ltd. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$26.78|
|52 Week High||US$26.90|
|52 Week Low||US$7.67|
|1 Month Change||0.22%|
|3 Month Change||48.78%|
|1 Year Change||40.36%|
|3 Year Change||50.37%|
|5 Year Change||103.26%|
|Change since IPO||101.96%|
Recent News & Updates
Analyst Forecasts For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging HigherApr 28
Analysts Just Shipped A Substantial Upgrade To Their Myovant Sciences Ltd. (NYSE:MYOV) EstimatesMay 14
New Forecasts: Here's What Analysts Think The Future Holds For Myovant Sciences Ltd. (NYSE:MYOV)Feb 17
Earnings Update: Myovant Sciences Ltd. (NYSE:MYOV) Just Reported And Analysts Are Boosting Their EstimatesFeb 13
Analysts' Revenue Estimates For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging HigherJan 12
Have Insiders Been Selling Myovant Sciences Ltd. (NYSE:MYOV) Shares This Year?Dec 23
Myovant Sciences (NYSE:MYOV) Shareholders Have Enjoyed A 60% Share Price GainNov 18
|MYOV||US Biotechs||US Market|
Return vs Industry: MYOV exceeded the US Biotechs industry which returned -14.4% over the past year.
Return vs Market: MYOV exceeded the US Market which returned -18.5% over the past year.
|MYOV Average Weekly Movement||11.9%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: MYOV is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: MYOV's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company’s lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction.
Myovant Sciences Ltd. Fundamentals Summary
|MYOV fundamental statistics|
Is MYOV overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MYOV income statement (TTM)|
|Cost of Revenue||US$185.41m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.96|
|Net Profit Margin||-56.88%|
How did MYOV perform over the long term?See historical performance and comparison